• 1
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947952.
  • 2
    Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356364.
  • 3
    Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ 2002 Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. J Pediatr 141: 644651.
  • 4
    Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 12931299.
  • 5
    Grissom LE, Harcke HT 2003 Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33: 226229.
  • 6
    Marini JC 2003 Do bisphosphonates make children's bones better or brittle? N Engl J Med 349: 423426.
  • 7
    Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26: 103109.
  • 8
    Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH 2002 Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease. Bone 31: 1218.
  • 9
    Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553559.
  • 10
    Parfitt AM 1990 Bone-forming cells in clinical conditions. In: HallBK (ed.) The Osteoblast and Osteocyte, vol. 1. Telford Press, Caldwell, NJ, USA, pp. 351429.
  • 11
    Park EA 1964 The imprinting of nutritional disturbances on the growing bone. Pediatrics 33: 815862.